BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33981577)

  • 1. Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-κB and MAPK activation.
    Guo W; Li H; Lou Y; Zhang Y; Wang J; Qian M; Wei H; Xiao J; Xu Y
    J Orthop Translat; 2021 May; 28():148-158. PubMed ID: 33981577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosavin suppresses osteoclastogenesis
    Zhang W; Zhang W; Huo L; Chai Y; Liu Z; Ren Z; Yu C
    Ann Transl Med; 2021 Mar; 9(5):383. PubMed ID: 33842604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
    Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
    J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
    Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting ERK/NF-κB pathway.
    Li Y; Zhuang Q; Tao L; Zheng K; Chen S; Yang Y; Feng C; Wang Z; Shi H; Shi J; Fang Y; Xiao L; Geng D; Wang Z
    Cell Prolif; 2022 Oct; 55(10):e13291. PubMed ID: 35708050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asiatic Acid Attenuates Osteoporotic Bone Loss in Ovariectomized Mice Through Inhibiting NF-kappaB/MAPK/ Protein Kinase B Signaling Pathway.
    Dong M; Zeng J; Yang C; Qiu Y; Wang X
    Front Pharmacol; 2022; 13():829741. PubMed ID: 35211021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological inhibition of protein S-palmitoylation suppresses osteoclastogenesis and ameliorates ovariectomy-induced bone loss.
    Ma L; Zhang L; Liao Z; Xiu C; Luo X; Luo N; Zhang L; He G; Chen J
    J Orthop Translat; 2023 Sep; 42():1-14. PubMed ID: 37521493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual effect of WIN-34B on osteogenesis and osteoclastogenesis in cytokine-induced mesenchymal stem cells and bone marrow cells.
    Seo BK; Ryu HK; Park YC; Huh JE; Baek YH
    J Ethnopharmacol; 2016 Dec; 193():227-236. PubMed ID: 27401292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytisine attenuates bone loss of ovariectomy mouse by preventing RANKL-induced osteoclastogenesis.
    Qian Z; Zhong Z; Ni S; Li D; Zhang F; Zhou Y; Kang Z; Qian J; Yu B
    J Cell Mol Med; 2020 Sep; 24(17):10112-10127. PubMed ID: 32790170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dencichine prevents ovariectomy-induced bone loss and inhibits osteoclastogenesis by inhibiting RANKL-associated NF-κB and MAPK signaling pathways.
    Cang D; Zou G; Yang C; Shen X; Li F; Wu Y; Ji B
    J Pharmacol Sci; 2021 Aug; 146(4):206-215. PubMed ID: 34116734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Saikosaponin a inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB and MAPK pathways.
    Zhou C; Liu W; He W; Wang H; Chen Q; Song H
    Int Immunopharmacol; 2015 Mar; 25(1):49-54. PubMed ID: 25617149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Picroside II Inhibits RANKL-Mediated Osteoclastogenesis by Attenuating the NF-κB and MAPKs Signaling Pathway In Vitro and Prevents Bone Loss in Lipopolysaccharide Treatment Mice.
    Yang X; Gao W; Wang B; Wang X; Guo H; Xiao Y; Kong L; Hao D
    J Cell Biochem; 2017 Dec; 118(12):4479-4486. PubMed ID: 28464271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel RANKL-targeted flavonoid glycoside prevents osteoporosis through inhibiting NFATc1 and reactive oxygen species.
    Hong G; Chen Z; Han X; Zhou L; Pang F; Wu R; Shen Y; He X; Hong Z; Li Z; He W; Wei Q
    Clin Transl Med; 2021 May; 11(5):e392. PubMed ID: 34047464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
    Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
    Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseurotin A Inhibits Osteoclastogenesis and Prevents Ovariectomized-Induced Bone Loss by Suppressing Reactive Oxygen Species.
    Chen K; Qiu P; Yuan Y; Zheng L; He J; Wang C; Guo Q; Kenny J; Liu Q; Zhao J; Chen J; Tickner J; Fan S; Lin X; Xu J
    Theranostics; 2019; 9(6):1634-1650. PubMed ID: 31037128
    [No Abstract]   [Full Text] [Related]  

  • 20. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.